To the Editor:

It has recently been shown in preclinical studies that local or systemic treatment with interleukin-12 (IL-12) produces profound antitumor effects causing regression of established tumors and tumor metastases.1,2 The antitumor activity of IL-12 is to a large extent mediated by interferon-γ (IFN-γ) secreted in increased amounts by T cells and natural killer (NK) cells.1 

IL-12 had initially been viewed as a synergistic hematopoietic growth factor in vitro.3 However, when administered in vivo to mice it caused a dose-dependent suppression of bone marrow hematopoiesis.4 Similarly, in phase I trial of IL-12 in patients with advanced malignancies it caused anemia, thrombocytopenia, lymphopenia, and neutropenia.5 

There is substantial evidence that cytokines (mainly IFN-γ) released during IL-12 treatment are implicated in the suppression of bone marrow hematopoiesis. However, both neutralization with monoclonal antibodies1 and reducing the release of IFN-γ (by means of predosing with IL-12)6,7 result in attenuation of the antitumor activity of IL-12, and thus cannot be considered as good methods to prevent the suppression of bone marrow hematopoiesis. In our previous experiments we showed that application of granulocyte colony-stimulating factor (G-CSF) results in correction of IL-12–induced granulocytopenia.8 However, coadministration of G-CSF with IL-12 led to even stronger suppression of thrombopoiesis. Moreover, as has been reported in a recent issue of BLOOD,pretreatment with IL-12 does not ameliorate the thrombocytopenia observed during subsequent administration of IL-12 to either humans or mice.7 

Because erythropoietin (Epo) is used in the treatment of anemia of cancer,9 and has also been shown to occasionally correct thrombocytopenia,10 we decided to evaluate whether it could prevent the development of some of the side effects induced by IL-12 treatment.

Administration of IL-12 (kindly provided by Genetics Institute, Boston, MA) at a daily dose of 0.1 μg for 7 consecutive days resulted in anemia and thrombocytopenia (Table 1). Epo (rhuErythropoietin, Eprex, Cilag) administered at two daily doses of 20 U for 7 consecutive days nonsignificantly increased the level of hemoglobin as compared with controls. In accordance with our expectations, application of Epo prevented the development of IL-12–induced anemia. Additionally, unexpectedly Epo was also found to prevent IL-12–induced decrease in platelet count. However, taking into account the somewhat weaker thrombopoietic activity of Epo in humans11 as compared with mice, it remains to be seen whether Epo could be effective in correcting IL-12–induced thrombocytopenia in tumor patients.

Table 1.

The Influence of IL-12 and/or Epo on the Number of Platelets and the Hemoglobin Concentration in Peripheral Blood

In Vivo Treatment Platelets (×109/mL) Hemoglobin (g/L)
0.1% BSA-PBS  1004.5 ± 195.4  189.5 ± 25.0 
Epo  853.6 ± 312.5  216.0 ± 21.9  
IL-12 612.9 ± 98.9-150 156.1 ± 8.5-150 
IL-12 + Epo 887.6 ± 193.9-151 205.5 ± 29.3-151 
In Vivo Treatment Platelets (×109/mL) Hemoglobin (g/L)
0.1% BSA-PBS  1004.5 ± 195.4  189.5 ± 25.0 
Epo  853.6 ± 312.5  216.0 ± 21.9  
IL-12 612.9 ± 98.9-150 156.1 ± 8.5-150 
IL-12 + Epo 887.6 ± 193.9-151 205.5 ± 29.3-151 

Five to seven 9-week-old B6D2F1 melanoma-bearing male mice were used per group. Mice were treated intraperitoneally with IL-12 (0.1 μg/injection) and/or Epo (20 U/injection given twice daily) or with 0.1% BSA-PBS for 7 consecutive days. Blood was collected on day 8, 12 hours after the last injection, and analyzed using Sysmex-820 cell counter (Sysmex, Kyoto, Japan) adjusted to the analysis of rodent cells. Results represent the mean ± SD.

F0-150

P < .01 versus controls.

F0-151

P < .01 versus IL-12–treated mice (Student'st-test).

Because hematopoietic growth factors may occasionally stimulate the growth of neoplasms, including solid tumors,12 13 we decided to examine the influence of Epo application on the growth of MmB16 melanoma. Epo did not influence tumor growth when given alone and did not decrease the antitumor activity of IL-12 in this particular tumor model (Fig 1A and B).

Fig. 1.

The effects of treatment with IL-12 and/or Epo on MmB16 melanoma growth in B6D2F1 mice. Mice were inoculated with 1 × 106 melanoma cells into the footpad of the right hind limb and treated with the intratumoral injections (days 7 to 13, arrows) of IL-12 (0.1 μg/injection), Epo (20 U/injection; twice daily), or IL-12 in combination with Epo (the same doses). Tumor volume was determined as described previously.15 (A) A pilot study with four B6D2F1 mice per group. * P < .05: IL-12- and IL-12+ Epo–treated mice versus controls; ▴, IL-12 + Epo; ◊, IL-12; ▿, control. (B) Additional experiment with five to six B6D2F1 mice in each of the groups. * P < .05: IL-12- and IL-12+ Epo–treated mice versus controls and Epo-treated mice; ** P < .01: IL-12- and IL-12 + Epo–treated mice versus controls and Epo-treated mice (Student's t-test); ▴, IL-12 + Epo; ◊, IL-12; ▪, Epo; ▿, control.

Fig. 1.

The effects of treatment with IL-12 and/or Epo on MmB16 melanoma growth in B6D2F1 mice. Mice were inoculated with 1 × 106 melanoma cells into the footpad of the right hind limb and treated with the intratumoral injections (days 7 to 13, arrows) of IL-12 (0.1 μg/injection), Epo (20 U/injection; twice daily), or IL-12 in combination with Epo (the same doses). Tumor volume was determined as described previously.15 (A) A pilot study with four B6D2F1 mice per group. * P < .05: IL-12- and IL-12+ Epo–treated mice versus controls; ▴, IL-12 + Epo; ◊, IL-12; ▿, control. (B) Additional experiment with five to six B6D2F1 mice in each of the groups. * P < .05: IL-12- and IL-12+ Epo–treated mice versus controls and Epo-treated mice; ** P < .01: IL-12- and IL-12 + Epo–treated mice versus controls and Epo-treated mice (Student's t-test); ▴, IL-12 + Epo; ◊, IL-12; ▪, Epo; ▿, control.

Close modal

As the antitumor activity of IL-12 may by potentiated by administration of some of the chemotherapeutics,14 it might be anticipated that IL-12 together with Epo could be successfully included into some of the combined chemoimmunotherapy schedules.

Supported by Grant No. 6 P207 058 07 from the State Committee for Scientific Research (K.B.N), Poland. Tomasz Stokłosa is a recipient of the Foundation for Polish Science Award.

1
Nastala
CL
Edington
HD
McKinney
TG
Tahara
H
Nalesnik
MA
Brunda
MJ
Gately
MK
Wolf
SF
Schreiber
RD
Storkus
WJ
Lotze
MT
Recombinant IL-12 administration induces tumor regression in association with IFN-γ production.
J Immunol
153
1994
1697
2
Lasek
W
Feleszko
W
Goła̧b
J
Stokłosa
T
Marczak
M
Da̧browska
A
Malejczyk
M
Jakóbisiak
M
Antitumor effects of the combination immunotherapy with IL-12 and TNF-α in mice.
Cancer Immunol Immunother
45
1997
100
3
Jacobsen
SEW
Veiby
OP
Smeland
EB
Cytotoxic lymphocyte maturation factor (Interleukin 12) is a synergistic growth factor for hematopoietic stem cells.
J Exp Med
178
1993
413
4
Eng
VM
Car
BD
Schnyder
B
Lorenz
M
Lugli
S
Aguet
M
Anderson
TD
Ryffel
B
Quesniaux
VFJ
The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon γ in vivo.
J Exp Med
181
1995
1893
5
Atkins
MB
Robertson
MJ
Gordon
M
Lotze
MT
DeCoste
M
DuBois
JS
Ritz
J
Sandler
AB
Edington
HD
Garzone
PD
Mier
JW
Canning
CM
Battiato
L
Tahara
H
Sherman
ML
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Clin Cancer Res
3
1997
409
6
Coughlin
CM
Wysocka
M
Trinchieri
G
Lee
WMF
The effect of interleukin 12 desensitization on the antitumor effects of recombinant interleukin 12.
Cancer Res
57
1997
2460
7
Leonard
JP
Sherman
ML
Fisher
GL
Buchanan
LJ
Larsen
G
Atkins
MB
Sosman
JA
Dutcher
JP
Vogelzang
NJ
Ryan
JL
Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production.
Blood
90
1997
2541
8
Goła̧b
J
Stokłosa
T
Zagoz˙dz˙on
R
Kaca
A
Giermasz
A
Pojda
Z
Machaj
E
Da̧browska
A
Feleszko
W
Lasek
W
Iwan-Osiecka
A
Jakóbisiak
M
G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in melanoma model in mice.
Ann Oncol
9
1998
63
9
Spivak
JL
Recombinant human erythropoietin and the anemia of cancer.
Blood
84
1995
997
10
Harrison
J
Kappas
A
Levere
RD
Lutton
JD
Chertkov
JL
Jiang
S
Abraham
NG
Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment.
Blood
82
1993
3574
11
Eschbach
JW
Abdulhadi
MH
Browne
JK
Delano
BG
Downing
MR
Egrie
JC
Evans
RW
Friedman
EA
Graber
SE
Haley
NR
Korbet
S
Krantz
SB
Lundin
AP
Nissenson
AR
Ogden
DA
Paganini
EP
Rader
B
Rutsky
EA
Stivelman
J
Stone
WJ
Teschan
P
van Stone
JC
van Wyck
DB
Zuckerman
K
Adamson
JW
Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
Ann Intern Med
111
1989
992
12
Segawa
K
Ueno
Y
Kataoka
In vivo tumor growth enhancement by granulocyte colony-stimulating factor.
Jpn J Cancer Res
82
1991
440
13
Feleszko
W
Giermasz
A
Goła̧b
J
Lasek
W
Kuc
K
Szperl
M
Jakóbisiak
M
Granulocyte-macrophage colony-stimulating factor accelerates growth of Lewis lung carcinoma in mice.
Cancer Lett
101
1996
193
14
Zagoz˙dz˙on
R
Stokłosa
T
Goła̧b
J
Giermasz
A
Kaca
A
Kultchitska
LA
Lasek
W
Jakóbisiak
ML
Combination tumor therapy with interleukin-12, cisplatin, and tumor necrosis factor-α of experimental melanoma in mice.
Anticancer Res
17
1997
4493
15
Lasek
W
Giermasz
A
Kuc
K
Wańkowicz
A
Goła̧b
J
Zagoz˙dz˙on
R
Stokłosa
T
Jakóbisiak
M
Potentiation of the antitumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between results of in vitro and in vivo studies.
Int J Cancer
66
1996
374
Sign in via your Institution